Abstract
BackgroundRecently, some studies reported the prognostic value of platelet-to-lymphocyte ratio (PLR) in patients with diffuse large B-cell lymphoma (DLBCL), however, the results varied from different studies. Therefore, we performed a meta-analysis to explore the prognostic value of PLR in DLBCL.MethodsA comprehensive literature retrieval was conducted by using PubMed, Embase, Web of Science, the Cochrane Library, the China National Knowledge Infrastructure (CNKI), and Wanfang. Pooled hazard ratio (HR) and 95% confidence interval (CI) were used to evaluate the association of PLR and overall survival (OS) and progression-free survival (PFS). Odd ratios (ORs) and 95% CIs for clinicopathological characteristics were statistically analyzed.ResultsEight studies with 1931 patients were included for meta-analysis. The pooled analysis indicated that elevated PLR was significantly associated with poor OS (HR = 1.73, 95% CI 1.29–2.31, p < 0.001), but not PFS (HR = 0.85, 95% CI 0.57–1.27, p = 0.438). Furthermore, elevated PLR was significantly associated with presentation of B symptoms (OR = 2.27, 95% CI 1.29–3.98, p = 0.004), elevated lactate dehydrogenase (LDH) (OR = 2.76, 95% CI 2.05–3.72, p < 0.001), higher tumor stage (OR = 2.22, 95% CI 1.66–2.98, p < 0.001), and Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≥ 2 (OR = 1.71, 95% CI 1.09–2.69, p = 0.019). However, elevated PLR was not significantly correlated with gender, age or cell of origin.ConclusionThis meta-analysis revealed that PLR may be an effective and noninvasive biomarker for poor prognosis and aggressive disease characteristics for patients with DLBCL.
Highlights
Some studies reported the prognostic value of platelet-to-lymphocyte ratio (PLR) in patients with diffuse large B-cell lymphoma (DLBCL), the results varied from different studies
Some studies [22, 23] demonstrated that PLR was a significant prognostic factor for DLBCL patients, whereas other studies failed to find the prognostic value of PLR [11, 13, 14]
The results showed that a high PLR was a significant prognostic marker for poorer overall survival (OS) (HR = 1.73, 95% confidence interval (CI) 1.29–2.31, p < 0.001)
Summary
Some studies reported the prognostic value of platelet-to-lymphocyte ratio (PLR) in patients with diffuse large B-cell lymphoma (DLBCL), the results varied from different studies. We performed a meta-analysis to explore the prognostic value of PLR in DLBCL. Diffuse large B-cell lymphoma (DLBCL) is the most frequent type of non-Hodgkin lymphoma, accounting for approximately 30–40% of all malignant lymphomas worldwide [1, 2]. DLBCL presents heterogeneous and aggressive status with different biological and clinical features [3]. Inflammatory responses are involved in different steps of cancer development [6]. Inflammation activity plays an important role in prognostication. The indexes derived from hematological parameters are investigated for prognosis of cancer patients in recent years. Plateletto-lymphocyte ratio (PLR) is calculated as platelet counts divided by lymphocyte counts.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have